Biotech

Market Context

Biotech is experiencing a dual-engine acceleration: a resurgent IPO market breaking records and a wave of large-cap M&A as pharma giants deploy capital to acquire validated assets. Simultaneously, AI-native biology companies are attracting institutional co-investments at unprecedented scale, with sovereign and pension funds like CalPERS entering directly as co-investors rather than through fund intermediaries — a structural shift that signals mainstream conviction in deep-tech biotech. The convergence of protein language models, in vivo cell therapy, and longevity science is pulling frontier capital into bets that would have seemed speculative just two years ago.

Investment Activity

• Lila Sciences raised a $2B Growth round co-led by CalPERS and NVentures at an $8.5B valuation, marking one of the largest single biotech rounds in recent memory.
• NewLimit raised a $435M Series C led by Founders Fund, valuing the longevity biotech at $3.1B.
• Chan Zuckerberg Biohub received a $500M Growth commitment from the Chan Zuckerberg Initiative to fund its hierarchical world-model-of-biology strategy.
• Avalyn Pharma raised $300M in its Nasdaq IPO at an $813M fully diluted valuation.
• Hemab Therapeutics raised $301.5M in a US IPO backed by Novo Holdings and RA Capital Management.
• Odyssey Therapeutics raised $304M in its Nasdaq IPO, having previously secured ~$726.5M in private funding.
• SonoThera raised $125M Series B led by Vida Ventures, ARK Invest, Leaps by Bayer, and Otsuka Pharmaceutical.
• Collate raised $95M Series A from Redpoint Ventures at a $1B valuation.
• Contraline closed a $92.5M Series B co-led by BVF Partners.
• Mana.bio raised a $19.5M seed round from NFX.
• Oorja Bio raised $30M in Series A financing.

Key Players

• Lila Sciences is building "Scientific Superintelligence" and has attracted the largest single biotech round in the dataset at $2B, with institutional co-investor CalPERS signaling pension fund conviction in frontier AI-bio.
• NewLimit is a longevity biotech co-founded by Coinbase CEO Brian Armstrong and former GV partner Blake Byers, now backed by Founders Fund at a $3.1B valuation, legitimizing epigenetic reprogramming as a mainstream VC thesis.
• Chan Zuckerberg Biohub is executing a deliberate, layered strategy to build hierarchical world models of biology (proteins → cells → systems), backed by $500M from CZI and anchored by the arrival of EvolutionaryScale co-founder Alex Rives as Head of Science.
• Nuvalent was acquired by GSK for $10.6B at a 40% premium, representing the largest M&A exit in the dataset and underscoring pharma's appetite for validated oncology assets.
• Parabilis Medicines set a new record for the largest VC-backed biotech IPO, surpassing Kailera Therapeutics which had taken the record just weeks prior, signaling a sustained IPO reopening.

Market Signals

• The biotech IPO market is in a record-breaking streak, with Parabilis Medicines setting the all-time VC-backed biotech IPO record, Kailera Therapeutics closing a $625M IPO just weeks earlier, and Kardigan targeting a $1.6B fully diluted valuation in its upcoming offering.
• M&A deal velocity is accelerating sharply: GSK acquired Nuvalent for $10.6B, Chiesi Group acquired KalVista Pharmaceuticals for $1.9B, Eli Lilly acquired Curevo Vaccine for up to $1.5B, Incyte acquired Vega Therapeutics for $1.25B upfront, and Johnson & Johnson acquired Firefly Bio for $1B — five acquisitions totaling over $16B in roughly two weeks.
• Institutional LP capital is entering biotech directly: CalPERS co-led Lila Sciences' $2B round as a direct co-investor, not through a fund, compressing traditional VC deal dynamics.
• Protein language models are emerging as a platform technology: Biohub released ESMFold2, folding 1.1 billion proteins, while ARC Institute open-sourced a genome language model trained on all available global genomic data, already used by Ohalo in plant breeding.
• Top investors by deal count over 28 days — Founders Fund (4 deals), General Catalyst (4 deals), Bessemer Venture Partners (3 deals), CalPERS (3 deals), GV (3 deals) — reflect a mix of pure-play VC and institutional capital converging on biotech.